Adjuvant Imatinib Study Updates Results

A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]

By |2018-10-30T13:56:09-04:00December 16th, 2015|Gleevec, News, Newsletter, Research, Survival Strategies|

Henzo Kenya Holds Psychological Support and Wellness Conference

Henzo Kenya,  the CML and GIST support organization in Kenya, Africa held a conference at the Nairobi Hospital in the New Lecture Theatre Hall on Psychological Support and Wellness [...]

By |2020-09-18T11:02:16-04:00November 3rd, 2015|Events, GIST Education, News, Patient Support|

Mechanisms of Disease Persistence in Gastrointestinal Stromal Tumors

By Tamas Ordog, LRG Research Team, Martin Zörnig and Yujiro Hayashi Dr. Tamas Ordog Gastrointestinal stromal tumors (GIST) represent a substantial proportion of human bone and soft tissue sarcomas.1 GIST are thought [...]

By |2019-10-31T12:01:09-04:00October 16th, 2015|News, Research|

GIST Pathology Report: The Key to Understanding Your GIST

After the diagnosis of GIST, a patient should take important steps to learn more about their particular disease so that they may find optimal care and treatment. This can be a very challenging and sometimes overwhelming task. Getting a copy of the surgical pathology report is one of those steps.

By |2026-01-11T15:47:43-05:00October 16th, 2015|News, Patient Support|

Immunotherapy: Game Changing Cancer Treatments

Two recent articles summarize the promise that immunotherapy provides for the future of cancer treatment. Immunotherapy refers to treatments that aid your own immune system in fighting cancer cells. The first, from U.S. News [...]

By |2018-11-05T14:35:28-05:00October 15th, 2015|Drug Treatment, News, Research|
Go to Top